This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019
Hamilton, Bermuda – 1 May 2019 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced schedule for reporting 2019 1st Quarter results. The filing stated:
-- JazzPharmaceuticalsplc(Nasdaq:JAZZ) todayannouncedthat itwillreport its2019 firstquarterfinancialresultsonTuesday,May 7,2019,after the close ofthefinancialmarkets. Companymanagementwill hosta liveaudiowebcastimmediatelyfollowingtheannouncement at4:30p.m. EDT/9:30p.m. IST todiscussfirstquarter 2019 financialresultsandprovidea businessandfinancialupdate.
Interestedpartiesmayaccessthe liveaudiowebcastvia theInvestorssectionoftheJazzPharmaceuticalswebsiteat www.jazzpharmaceuticals.com. Pleaseconnect tothe websiteprior tothe startoftheconferencecall toensureadequate timeforanysoftwaredownloadsthat maybenecessarytolistentothewebcast. Areplay ofthewebcastwillbearchivedonthe websiteforatleastoneweek.
Audiowebcast/conference call:
U.S.Dial-InNumber:+1855 3537924International Dial-InNumber: +1503 3436056Passcode:6667859
A replay oftheconference call will be available through May14,2019andaccessible through one ofthefollowingtelephone numbers,using thepasscode below:
Replay U.S.Dial-In Number: +1855 8592056
ReplayInternational Dial-InNumber:+1 4045373406
Passcode:6667859
AboutJazzPharmaceuticals
JazzPharmaceuticalsplc(Nasdaq:JAZZ), aglobal biopharmaceutical company,isdedicatedtodevelopinglife-changingmedicinesforpeoplewith limitedornooptions.Asa leader in sleepmedicine and with agrowinghematology/oncologyportfolio, Jazzhasa diverse portfolio ofproductsand productcandidatesin development, and isfocused ontransforming biopharmaceuticaldiscoveriesinto novel medicines. JazzPharmaceuticalsmarketsXyrem® (sodium oxybate)oralsolution,Erwinaze®(asparaginaseErwinia chrysanthemi),Defitelio® (defibrotide sodium) andVyxeos®(daunorubicinand cytarabine) liposomeforinjection intheU.S. andmarketsErwinase®,Defitelio®(defibrotide)and Vyxeos®44 mg/100mgpowderfor concentratefor solutionfor infusionincountriesoutsidetheU.S. For country-specificproduct information,please
visitwww.jazzpharmaceuticals.com/medicines.For moreinformation,pleasevisitwww.jazzpharmaceuticals.comandfollowusonTwitter at@JazzPharma.